English
English Indonesia Türkçe Deutsch Español Português Pусский Français Italiano Nederlands Polski العربية ไทย Tiếng Việt 繁體中文 简体中文 日本語 한국어

#elcc search results

AtkinsonCentre's profile picture. The Atkinson Centre is a research centre committed to inform public discourse, public policy & professional learning of ECEs & elementary school teachers.
Atkinson Centre
 @AtkinsonCentre
Oct 31

The HUB is live! Meet the leaders driving research that informs equity & opportunity in #ELCC Today’s Spotlight: Dr. Jessie-Lee McIsaac, Assoc. Prof. & Tier II 🇨🇦 Research Chair in Early Childhood, Faculty of Ed, @MSVU_Halifax Explore more at eceknowledgehub.ca

AtkinsonCentre's tweet image. The HUB is live! Meet the leaders driving research that informs equity & opportunity in #ELCC Today’s Spotlight: Dr. Jessie-Lee McIsaac, Assoc. Prof. & Tier II 🇨🇦 Research Chair in Early Childhood, Faculty of Ed, @MSVU_Halifax Explore more at eceknowledgehub.ca
0
1
2
0
151
gerryhanna's profile picture. Radiation Oncologist at SLRON @stjamesdublin, Marie Curie Chair at @TCDRadTher and @CancerInstIRE wouldbe cyclist, sometimes pianist. Views are my own, RTs not
Gerry Hanna
@gerryhanna
Mar 21, 2024

Breaking from #ELCC (discounting a press release…) 🚨 PACIFIC-2 is negative. No improvement with concurrent and adjuvant Durvalumab with chemo radiotherapy in stage III NSCLC @JeffBradleyMD presents at #ELCC24

gerryhanna's tweet image. Breaking from #ELCC (discounting a press release…) 🚨 PACIFIC-2 is negative. No improvement with concurrent and adjuvant Durvalumab with chemo radiotherapy in stage III NSCLC @JeffBradleyMD presents at #ELCC24
gerryhanna's tweet image. Breaking from #ELCC (discounting a press release…) 🚨 PACIFIC-2 is negative. No improvement with concurrent and adjuvant Durvalumab with chemo radiotherapy in stage III NSCLC @JeffBradleyMD presents at #ELCC24
gerryhanna's tweet image. Breaking from #ELCC (discounting a press release…) 🚨 PACIFIC-2 is negative. No improvement with concurrent and adjuvant Durvalumab with chemo radiotherapy in stage III NSCLC @JeffBradleyMD presents at #ELCC24
gerryhanna's tweet image. Breaking from #ELCC (discounting a press release…) 🚨 PACIFIC-2 is negative. No improvement with concurrent and adjuvant Durvalumab with chemo radiotherapy in stage III NSCLC @JeffBradleyMD presents at #ELCC24
7
37
89
28
40K
DrJNaidoo's profile picture. Professor of Medical Oncology @CancerCentreIre | Thoracic Oncologist | Immunotherapy & Immune toxicity | Adjunct faculty Johns Hopkins University
Jarushka Naidoo
 @DrJNaidoo
Mar 23, 2024

#ELCC ADCs: the promising new therapy? Discussing all things antibody-drug conjugates, join me, #EgbertSmit #IgnatioWistuba & ⁦@peters_solange⁩ in Forum Hall today at 10am #ESMOambassadors #ELCC24 ⁦@myESMO⁩ ⁦⁦@CancerCentreIre⁩ ⁦@RCSI_Irl⁩⁩

DrJNaidoo's tweet image. #ELCC ADCs: the promising new therapy? Discussing all things antibody-drug conjugates, join me, #EgbertSmit #IgnatioWistuba & ⁦@peters_solange⁩ in Forum Hall today at 10am #ESMOambassadors #ELCC24 ⁦@myESMO⁩ ⁦⁦@CancerCentreIre⁩ ⁦@RCSI_Irl⁩⁩
2
10
38
1
5K
bmassutis's profile picture. Medical oncologist, clinical researcher. Focus lung cancer. Born in Majorca. World citizen. Major concerns: human inequality and blue planet environment. @gecp
Bartomeu Massuti
 @bmassutis
Mar 30, 2023

EMPOWER 3 updated results: Cemiplimab added to CT improves outcomes for both histologies but not for PD-L1 negative tumors subgroups at #ELCC 2023 ⁦@OncoAlert⁩

bmassutis's tweet image. EMPOWER 3 updated results: Cemiplimab added to CT improves outcomes for both histologies but not for PD-L1 negative tumors subgroups at #ELCC 2023 ⁦@OncoAlert⁩
bmassutis's tweet image. EMPOWER 3 updated results: Cemiplimab added to CT improves outcomes for both histologies but not for PD-L1 negative tumors subgroups at #ELCC 2023 ⁦@OncoAlert⁩
1
11
22
3
3K
bmassutis's profile picture. Medical oncologist, clinical researcher. Focus lung cancer. Born in Majorca. World citizen. Major concerns: human inequality and blue planet environment. @gecp
Bartomeu Massuti
 @bmassutis
Mar 30, 2023

Next challenge in Perioperative approach in NSCLC: tailoring treatment according risk but value of addition of postop therapy need to be confirmed in specific designed trials ⁦@APassaroMD⁩ ⁦@MARIANOPROVENCI⁩ ⁦@FordePatrick⁩ @OncoAlert at #ELCC #LCSM

bmassutis's tweet image. Next challenge in Perioperative approach in NSCLC: tailoring treatment according risk but value of addition of postop therapy need to be confirmed in specific designed trials ⁦@APassaroMD⁩ ⁦@MARIANOPROVENCI⁩ ⁦@FordePatrick⁩ @OncoAlert at #ELCC #LCSM
0
7
22
2
4K
bmassutis's profile picture. Medical oncologist, clinical researcher. Focus lung cancer. Born in Majorca. World citizen. Major concerns: human inequality and blue planet environment. @gecp
Bartomeu Massuti
 @bmassutis
Mar 30, 2023

Relapsed SCLC another frustrating scenario: Topotecan poor results are not yet improved but research continues #ELCC ⁦@OncoAlert⁩

bmassutis's tweet image. Relapsed SCLC another frustrating scenario: Topotecan poor results are not yet improved but research continues #ELCC ⁦@OncoAlert⁩
bmassutis's tweet image. Relapsed SCLC another frustrating scenario: Topotecan poor results are not yet improved but research continues #ELCC ⁦@OncoAlert⁩
0
6
10
3
2K
mkmoutafi's profile picture. Oncology Fellow @AttikonHospital & ResearchAffiliate @YaleMed| YOC Committee @ESMO|@H_N_C_I_G | MD,PhD @uoaofficial | #biomarkers #immunoonc #ESMOYOC
Myrto K. Moutafi
 @mkmoutafi
Mar 20, 2024

Join us at the ESMO YOC mentorship session in the foyer at the ELCC conference! See you there at 15:45 today! @EMariamidze @DrHongchengZhu #ELCC #YOC #Oncology #Mentorship

mkmoutafi's tweet image. Join us at the ESMO YOC mentorship session in the foyer at the ELCC conference! See you there at 15:45 today! @EMariamidze @DrHongchengZhu #ELCC #YOC #Oncology #Mentorship
0
1
27
0
880
bmassutis's profile picture. Medical oncologist, clinical researcher. Focus lung cancer. Born in Majorca. World citizen. Major concerns: human inequality and blue planet environment. @gecp
Bartomeu Massuti
 @bmassutis
Mar 30, 2023

Updated CM 816 at #ELCC 2023 confirms efficacy of neoadjuvant chemo immunotherapy with reduction of extrathoracic recurrence and Inflamatory signature might predictive ⁦@MARIANOPROVENCI⁩ ⁦@OncoAlert⁩

bmassutis's tweet image. Updated CM 816 at #ELCC 2023 confirms efficacy of neoadjuvant chemo immunotherapy with reduction of extrathoracic recurrence and Inflamatory signature might predictive ⁦@MARIANOPROVENCI⁩ ⁦@OncoAlert⁩
bmassutis's tweet image. Updated CM 816 at #ELCC 2023 confirms efficacy of neoadjuvant chemo immunotherapy with reduction of extrathoracic recurrence and Inflamatory signature might predictive ⁦@MARIANOPROVENCI⁩ ⁦@OncoAlert⁩
bmassutis's tweet image. Updated CM 816 at #ELCC 2023 confirms efficacy of neoadjuvant chemo immunotherapy with reduction of extrathoracic recurrence and Inflamatory signature might predictive ⁦@MARIANOPROVENCI⁩ ⁦@OncoAlert⁩
bmassutis's tweet image. Updated CM 816 at #ELCC 2023 confirms efficacy of neoadjuvant chemo immunotherapy with reduction of extrathoracic recurrence and Inflamatory signature might predictive ⁦@MARIANOPROVENCI⁩ ⁦@OncoAlert⁩
0
8
14
3
2K
footpri37168690's profile picture. 名古屋、本山駅から徒歩3分のリフレクソロジーサロンでした(閉店しました)。お客様が世界一、力の抜ける店を目指してました。元店主はMotoGPとEWCの速報を書く仕事もしています。店主だった人のアカウント→ @screaminjay
foot print
 @footpri37168690
Oct 17, 2023

#さんぱつはさみまん #elcc に持って行くのは3?4??回目。何度もやってる子はこれ結構好きーと言ってハサミで切り取ってくれたり、遂には新種⁉︎を生み出す子も居た！ @ehi_chan 喜ばれてるよー♡

footpri37168690's tweet image. #さんぱつはさみまん #elcc に持って行くのは3?4??回目。何度もやってる子はこれ結構好きーと言ってハサミで切り取ってくれたり、遂には新種⁉︎を生み出す子も居た！ @ehi_chan 喜ばれてるよー♡
1
1
8
0
396
gwalls89's profile picture. Clinical Oncologist | Researcher | 2023 WashU Fulbright Scholar
Gerard Walls
 @gwalls89
Mar 21, 2024

A to Z of cardiac substructures from @KathrynBanfill to open the @ESTRO_RT session #ELCC! Key msgs: - dose constraints outstanding - AI autocontours can help - still in research phase - individual pt factors v imp too

gwalls89's tweet image. A to Z of cardiac substructures from @KathrynBanfill to open the @ESTRO_RT session #ELCC! Key msgs: - dose constraints outstanding - AI autocontours can help - still in research phase - individual pt factors v imp too
gwalls89's tweet image. A to Z of cardiac substructures from @KathrynBanfill to open the @ESTRO_RT session #ELCC! Key msgs: - dose constraints outstanding - AI autocontours can help - still in research phase - individual pt factors v imp too
gwalls89's tweet image. A to Z of cardiac substructures from @KathrynBanfill to open the @ESTRO_RT session #ELCC! Key msgs: - dose constraints outstanding - AI autocontours can help - still in research phase - individual pt factors v imp too
gwalls89's tweet image. A to Z of cardiac substructures from @KathrynBanfill to open the @ESTRO_RT session #ELCC! Key msgs: - dose constraints outstanding - AI autocontours can help - still in research phase - individual pt factors v imp too
3
6
26
2
2K
bmassutis's profile picture. Medical oncologist, clinical researcher. Focus lung cancer. Born in Majorca. World citizen. Major concerns: human inequality and blue planet environment. @gecp
Bartomeu Massuti
 @bmassutis
Mar 30, 2023

Difficult and frustrating issue: 2nd line after CT-IT in metastatic NSCLC: How to overcome limited and older Docetaxel results? #ELCC ⁦@OncoAlert⁩

bmassutis's tweet image. Difficult and frustrating issue: 2nd line after CT-IT in metastatic NSCLC: How to overcome limited and older Docetaxel results? #ELCC ⁦@OncoAlert⁩
bmassutis's tweet image. Difficult and frustrating issue: 2nd line after CT-IT in metastatic NSCLC: How to overcome limited and older Docetaxel results? #ELCC ⁦@OncoAlert⁩
1
3
9
1
2K
ValsamoA's profile picture. Director, @MolecularOncLab & @HopkinsThoracic Biorepository Co-leader, Molecular Tumor Board @hopkinskimmel. Bringing multi-omics discoveries into IO trials.
Elsa Anagnostou
 @ValsamoA
Mar 30, 2023

What a treat to end a fantastic day 2 of #ELCC with a visit to the Arken museum of modern art #Copenhagen & dinner with old and new friends! @myESMO @IASLC @NReguart @MartinReck2

1
4
22
1
5K
bmassutis's profile picture. Medical oncologist, clinical researcher. Focus lung cancer. Born in Majorca. World citizen. Major concerns: human inequality and blue planet environment. @gecp
Bartomeu Massuti
 @bmassutis
Mar 30, 2023

CONTACT 01 No significant differences in overall survival for Atezolizumab plus Cabozantinib compared to Docetaxel IN pretreated NSCLC metastatic patients #ELCC 2023 #lcsm ⁦@OncoAlert⁩

bmassutis's tweet image. CONTACT 01 No significant differences in overall survival for Atezolizumab plus Cabozantinib compared to Docetaxel IN pretreated NSCLC metastatic patients #ELCC 2023 #lcsm ⁦@OncoAlert⁩
bmassutis's tweet image. CONTACT 01 No significant differences in overall survival for Atezolizumab plus Cabozantinib compared to Docetaxel IN pretreated NSCLC metastatic patients #ELCC 2023 #lcsm ⁦@OncoAlert⁩
1
2
8
2
2K
DrJNaidoo's profile picture. Professor of Medical Oncology @CancerCentreIre | Thoracic Oncologist | Immunotherapy & Immune toxicity | Adjunct faculty Johns Hopkins University
Jarushka Naidoo
 @DrJNaidoo
Mar 30, 2023

#ELCC Day 1 Highlight: Amivantamab long-term outcomes + biology in EGFR exon20ins+ NSCLC: - 48% pts have clinical benefit at 1yr - 47.2% pts alive at 2yrs - Baseline ctDNA alteratns in RAS/RAF/MEK assoc with less time on tx @myESMO @Piuchagarrido #LCSM dailyreporter.esmo.org/european-lung-…

DrJNaidoo's tweet image. #ELCC Day 1 Highlight: Amivantamab long-term outcomes + biology in EGFR exon20ins+ NSCLC: - 48% pts have clinical benefit at 1yr - 47.2% pts alive at 2yrs - Baseline ctDNA alteratns in RAS/RAF/MEK assoc with less time on tx @myESMO @Piuchagarrido #LCSM dailyreporter.esmo.org/european-lung-…
0
25
62
12
9K
JennaSudds's profile picture. Your Member of Parliament for Kanata. Tech Enthusiast. Mom to 3 amazing daughters. 🚗⚡️🌱
Jenna Sudds
 @JennaSudds
Oct 30, 2024

Allison and I agreed, early childhood educators are at the heart of our child care system. As Women’s History Month comes to an end, we remain committed to supporting women, including this essential workforce. #ELCC #Childcare @momsat_work

15
17
39
1
2K
TableTennisENG's profile picture. 🏓 🏴󠁧󠁢󠁥󠁮󠁧󠁿 1921-2021 #TTE100 💯 The governing body for table tennis in England. See also: @TTE_Development | @ping_tweets
Table Tennis England
@TableTennisENG
Jun 4, 2024

On Sunday 2nd June the English Leagues Cup Competition took place at the Draycott & Long Eaton TTC 🏓 Watch the winning moment as the Central London A Team clinched Wilmott Cup glory, and see which other leagues were crowned victorious 🏆🎉 #tabletennisvideos #ELCC

0
1
1
0
875
ESOncology's profile picture. Updates on events, activities, and opportunities held by the European School of Oncology, e-learning activities, and news from the ESO College!
ESOncology
 @ESOncology
Mar 30, 2023

Welcome to the 3rd edition of the 𝐂𝐞𝐫𝐭𝐢𝐟𝐢𝐜𝐚𝐭𝐞 𝐨𝐟 𝐀𝐝𝐯𝐚𝐧𝐜𝐞𝐝 𝐒𝐭𝐮𝐝𝐢𝐞𝐬 𝐢𝐧 #𝐋𝐮𝐧𝐠 𝐜𝐚𝐧𝐜𝐞𝐫 organised by ESO and the University of Zurich. The participants and faculty meet for the first in-person seminar during the #ELCC 2023 in Copenhagen.

ESOncology's tweet image. Welcome to the 3rd edition of the 𝐂𝐞𝐫𝐭𝐢𝐟𝐢𝐜𝐚𝐭𝐞 𝐨𝐟 𝐀𝐝𝐯𝐚𝐧𝐜𝐞𝐝 𝐒𝐭𝐮𝐝𝐢𝐞𝐬 𝐢𝐧 #𝐋𝐮𝐧𝐠 𝐜𝐚𝐧𝐜𝐞𝐫 organised by ESO and the University of Zurich. The participants and faculty meet for the first in-person seminar during the #ELCC 2023 in Copenhagen.
0
1
11
0
783
AtkinsonCentre's profile picture. The Atkinson Centre is a research centre committed to inform public discourse, public policy & professional learning of ECEs & elementary school teachers.
Atkinson Centre
 @AtkinsonCentre
Oct 31

The HUB is live! Meet the leaders driving research that informs equity & opportunity in #ELCC Today’s Spotlight: Dr. Jessie-Lee McIsaac, Assoc. Prof. & Tier II 🇨🇦 Research Chair in Early Childhood, Faculty of Ed, @MSVU_Halifax Explore more at eceknowledgehub.ca

AtkinsonCentre's tweet image. The HUB is live! Meet the leaders driving research that informs equity & opportunity in #ELCC Today’s Spotlight: Dr. Jessie-Lee McIsaac, Assoc. Prof. & Tier II 🇨🇦 Research Chair in Early Childhood, Faculty of Ed, @MSVU_Halifax Explore more at eceknowledgehub.ca
0
1
2
0
151
LatamConverge's profile picture. CCLATAM, pioneering think tank dedicated to advancing the realms of policy discussions and transformative change across the diverse landscape of Latin America.
Center for Latin America Convergence
@LatamConverge
Sep 9

🌎✨ The new #ElCC #42 is live! In this edition: ▪️ Washington’s security-first diplomacy vs. EU’s bet on Mercosur trade ▪️ Exclusive talk w/ 🇸🇻 Amb. @MilenaMayorga on #ElSalvador as a regional hub ▪️ Shifts in illicit markets & U.S.–LATAM cooperation ▪️ Market updates from…

cc-latam.org

El CC - CC Latam

EL CC Below you’ll be able to find all editions of El CC, our newsletter, to date so you can access them whenever you prefer. #44 The Agency or Irrelevance Issue #44 #43 Latam’s Digital Rights Issue...

Source: cc-latam.org
0
2
3
0
776
IONCOLOGYLung's profile picture. Welcome to the forefront of Thoracic Oncology Frontier! We deliver ​​cutting-edge advancements​​, ​​critical conference insights​​, and ​​expert interviews.
Thoracic Oncology Frontier
 @IONCOLOGYLung
Sep 2

#ELCC 2025｜Virginie Westeel: BR.31 trial: Adjuvant IO therapy failed to to reduce the recurrence rate or alter the recurrence pattern. ☹️no difference in terms of incidence of recurrences and second primaries. @IASLC #NSCLC #lungcancer youtu.be/7QGVSqDs0zE?si… via @YouTube

IONCOLOGYLung's tweet card. ELCC 2025｜Virginie Westeel: BR.31 trial: Adjuvant IO therapy failed...

youtube.com

YouTube

ELCC 2025｜Virginie Westeel: BR.31 trial: Adjuvant IO therapy failed...

Source: youtube.com
0
0
0
0
34
IONCOLOGYLung's profile picture. Welcome to the forefront of Thoracic Oncology Frontier! We deliver ​​cutting-edge advancements​​, ​​critical conference insights​​, and ​​expert interviews.
Thoracic Oncology Frontier
 @IONCOLOGYLung
Sep 1

#ELCC 2025｜Dr. Antonin Levy: Controversies and Clinical Challenges of oligometastatic lung cancer 🙌Definition of Oligometastatic Disease 🙌Breakthroughs in Oligometastatic Lung Cancer @IASLC #elcc #lungcancer youtu.be/Y7-GPRue3rM?si… via @YouTube

IONCOLOGYLung's tweet card. ELCC 2025｜Dr. Antonin Levy: Controversies and Clinical Challenges of...

youtube.com

YouTube

ELCC 2025｜Dr. Antonin Levy: Controversies and Clinical Challenges of...

Source: youtube.com
0
0
0
0
56
IONCOLOGYLung's profile picture. Welcome to the forefront of Thoracic Oncology Frontier! We deliver ​​cutting-edge advancements​​, ​​critical conference insights​​, and ​​expert interviews.
Thoracic Oncology Frontier
 @IONCOLOGYLung
Sep 1

#ELCC 2025｜Dr. Kersti Oselin：Novel Therapies and Targeted Pathways in Small Cell Lung Cancer ✍️Novel Therapies in SCLC ✍️Future Research Directions in ES-SCLC @IASLC #lungcancer #sclc youtu.be/8Wn_K3tMaLM?si… via @YouTube

IONCOLOGYLung's tweet card. ELCC 2025｜Dr. Kersti Oselin：Novel Therapies and Targeted Pathways in...

youtube.com

YouTube

ELCC 2025｜Dr. Kersti Oselin：Novel Therapies and Targeted Pathways in...

Source: youtube.com
0
0
0
0
35
IONCOLOGYLung's profile picture. Welcome to the forefront of Thoracic Oncology Frontier! We deliver ​​cutting-edge advancements​​, ​​critical conference insights​​, and ​​expert interviews.
Thoracic Oncology Frontier
 @IONCOLOGYLung
Aug 29

#ELCC 2025｜Dr. Perol shares #MARIPOSA Trial: Who Benefits Most & Risk Stratification. @IASLC #lungcancer #Cancer 🧐The ideal patients​​ for the combination therapy. ❓Risk stratification​​? 💡Practical implications​​ for clinicians. youtu.be/VH-gxpjPWuU?si… via @YouTube

IONCOLOGYLung's tweet card. ELCC 2025｜Dr. Perol shares MARIPOSA Trial: Who Benefits Most & Risk...

youtube.com

YouTube

ELCC 2025｜Dr. Perol shares MARIPOSA Trial: Who Benefits Most & Risk...

Source: youtube.com
0
0
0
0
25
IONCOLOGYLung's profile picture. Welcome to the forefront of Thoracic Oncology Frontier! We deliver ​​cutting-edge advancements​​, ​​critical conference insights​​, and ​​expert interviews.
Thoracic Oncology Frontier
 @IONCOLOGYLung
Aug 26

HOT DEBATE🗣️🗣️ #ELCC 2025｜@IASLC Presient Dr. Paul van Schil: Should Mediastinal Restaging Be Routine After Neoadjuvant Chemo-IO in #NSCLC？ youtu.be/AF-UTkBBiU0?si… via @YouTube

IONCOLOGYLung's tweet card. ELCC 2025｜Dr. Paul van Schil: Should Mediastinal Restaging Be Routine...

youtube.com

YouTube

ELCC 2025｜Dr. Paul van Schil: Should Mediastinal Restaging Be Routine...

Source: youtube.com
0
0
0
0
30
AtkinsonCentre's profile picture. The Atkinson Centre is a research centre committed to inform public discourse, public policy & professional learning of ECEs & elementary school teachers.
Atkinson Centre
 @AtkinsonCentre
Aug 21

ICYMI - Why child-care vouchers aren’t the answer for working families this fall #ChildCare #ECinCanada #ELCC @ConversationCA @danielfoster0 @Kerry_earlyyear theconversation.com/why-child-care…

AtkinsonCentre's tweet image. ICYMI - Why child-care vouchers aren’t the answer for working families this fall #ChildCare #ECinCanada #ELCC @ConversationCA @danielfoster0 @Kerry_earlyyear theconversation.com/why-child-care…
0
0
0
0
37
AtkinsonCentre's profile picture. The Atkinson Centre is a research centre committed to inform public discourse, public policy & professional learning of ECEs & elementary school teachers.
Atkinson Centre
 @AtkinsonCentre
Aug 18

ICYMI - Why child-care vouchers aren’t the answer for working families this fall theconversation.com/why-child-care… @ConversationCA @danielfoster0 @Kerry_earlyyear #ChildCare #ECinCanada #ELCC

AtkinsonCentre's tweet image. ICYMI - Why child-care vouchers aren’t the answer for working families this fall theconversation.com/why-child-care… @ConversationCA @danielfoster0 @Kerry_earlyyear #ChildCare #ECinCanada #ELCC
0
3
2
1
107
PowwrSoftware's profile picture. Market leading software provider for the energy and utilities sector
POWWR
 @PowwrSoftware
Jul 1

We're ready for you! If you're attending #ELCC today in London, make sure you stop by booth number one to say hi to the POWWR team.

PowwrSoftware's tweet image. We're ready for you! If you're attending #ELCC today in London, make sure you stop by booth number one to say hi to the POWWR team.
0
0
0
0
10
ISAssoc's profile picture. The strategies and tools for your company to stay relevant throughout industry change ⚙️ Leading The Channel Forward®
@ISAssoc
 @ISAssoc
Jun 26

Leadership is not a waiting game. ISA's ELCC program gives you the skills and signal to take your seat with confidence. Click the link below and make your move today. isapartners.org/elcc #ELCC #MROP #LeadershipJourney

ISAssoc's tweet image. Leadership is not a waiting game. ISA's ELCC program gives you the skills and signal to take your seat with confidence. Click the link below and make your move today. isapartners.org/elcc #ELCC #MROP #LeadershipJourney
0
0
0
0
15
PowwrSoftware's profile picture. Market leading software provider for the energy and utilities sector
POWWR
 @PowwrSoftware
Jun 24

We’re headed to #ELCC 2025 and will be part of the Growth & Tech for TPIs panel! Our own David Sheldrake will dive into how AI, smart data & innovation are reshaping the TPI landscape. Grab a free ticket to the event here: hubs.ly/Q03t6CP70

PowwrSoftware's tweet image. We’re headed to #ELCC 2025 and will be part of the Growth & Tech for TPIs panel! Our own David Sheldrake will dive into how AI, smart data & innovation are reshaping the TPI landscape. Grab a free ticket to the event here: hubs.ly/Q03t6CP70
0
0
0
0
23
ISAssoc's profile picture. The strategies and tools for your company to stay relevant throughout industry change ⚙️ Leading The Channel Forward®
@ISAssoc
 @ISAssoc
Jun 13

Your next move just showed up. ELCC helps emerging leaders stand out, speak up, and drive real impact in the industrial channel. Certification that gets you noticed starts here. Click the link in the comments to get started. #ELCC #MROP #ChannelLeadership

ISAssoc's tweet image. Your next move just showed up. ELCC helps emerging leaders stand out, speak up, and drive real impact in the industrial channel. Certification that gets you noticed starts here. Click the link in the comments to get started. #ELCC #MROP #ChannelLeadership
0
0
0
0
15
JulienMazieres's profile picture. MD, PhD, Prof of Respiratory Medicine, Thoracic Oncology Specialist @CHUdeToulouse, @IUCToncopole. Researcher, INSERM @crctoncopole #LCSM 🏃‍♂️ 🚴 🏉
Julien Mazieres
 @JulienMazieres
Apr 11, 2018

Congrats to @barlesi for his highly deserved award #ELCC

JulienMazieres's tweet image. Congrats to @barlesi for his highly deserved award #ELCC
0
7
20
0
0
vankayak's profile picture. Secretary of State for Sport. MP Burlington North - Milton West. Athlete. Physical Activity advocate. 4xSummer Olympian 🥇🥈🥈🥉🇨🇦 (he/him)
Adam van Koeverden
 @vankayak
Nov 18, 2021

Ontario families deserve the same $10/day childcare plan as the rest of Canada! #ELCC #Childcare

vankayak's tweet image. Ontario families deserve the same $10/day childcare plan as the rest of Canada! #ELCC #Childcare
29
189
761
4
0
AndreasC466's profile picture. Chair Department of Nursing Chair and Founder- European Cancer Communities Foundation Professor of Oncology and Palliative Care. 🇨🇾🇪🇺
Andreas Charalambous
 @AndreasC466
Apr 10, 2019

Mental preparation just before #ELCC #Geneva

AndreasC466's tweet image. Mental preparation just before #ELCC #Geneva
1
0
8
0
0
DrJNaidoo's profile picture. Professor of Medical Oncology @CancerCentreIre | Thoracic Oncologist | Immunotherapy & Immune toxicity | Adjunct faculty Johns Hopkins University
Jarushka Naidoo
 @DrJNaidoo
Mar 31, 2022

#ELCC Ph II NEOS trial: Neoadjuvant osimertinib in early stage EGFR-mt NSCLC presented by Chao Lyu: - 88 pts screened, 40 pts treated - ORR 71%, DCR 100%, MPR 11% - 7.5% G3+ TRAEs Interesting data of this popular approach in NSCLC! @OncoAlert #LCSM

DrJNaidoo's tweet image. #ELCC Ph II NEOS trial: Neoadjuvant osimertinib in early stage EGFR-mt NSCLC presented by Chao Lyu: - 88 pts screened, 40 pts treated - ORR 71%, DCR 100%, MPR 11% - 7.5% G3+ TRAEs Interesting data of this popular approach in NSCLC! @OncoAlert #LCSM
DrJNaidoo's tweet image. #ELCC Ph II NEOS trial: Neoadjuvant osimertinib in early stage EGFR-mt NSCLC presented by Chao Lyu: - 88 pts screened, 40 pts treated - ORR 71%, DCR 100%, MPR 11% - 7.5% G3+ TRAEs Interesting data of this popular approach in NSCLC! @OncoAlert #LCSM
1
28
62
10
0
MCCAHOUSE's profile picture. MCCA advocates for a quality system of child care, advances early learning and child care education as a profession, and provides services to our members.
MB Child Care Assoc.
 @MCCAHOUSE
Feb 25, 2019

In Ottawa at the ELCC Data & Research Conference. #cdnpoli #elcc #childcare

MCCAHOUSE's tweet image. In Ottawa at the ELCC Data & Research Conference. #cdnpoli #elcc #childcare
0
7
8
0
0
DrJNaidoo's profile picture. Professor of Medical Oncology @CancerCentreIre | Thoracic Oncologist | Immunotherapy & Immune toxicity | Adjunct faculty Johns Hopkins University
Jarushka Naidoo
 @DrJNaidoo
Mar 31, 2022

#ELCC Longerm survivors (LTS) from 1L CASPIAN trial in ES SCLC: - 94 pts were LTS (mfollow-up 39.4mo): 16% D+EP; 14% D+T+EP; 9% EP - Higher proportn of pts treated with D+T+EP and PDL1 >1% were LTS at 18mo + 36mo (not TMB) - More LTS pts completed EPx4 @OncoAlert @myESMO #LCSM

DrJNaidoo's tweet image. #ELCC Longerm survivors (LTS) from 1L CASPIAN trial in ES SCLC: - 94 pts were LTS (mfollow-up 39.4mo): 16% D+EP; 14% D+T+EP; 9% EP - Higher proportn of pts treated with D+T+EP and PDL1 >1% were LTS at 18mo + 36mo (not TMB) - More LTS pts completed EPx4 @OncoAlert @myESMO #LCSM
DrJNaidoo's tweet image. #ELCC Longerm survivors (LTS) from 1L CASPIAN trial in ES SCLC: - 94 pts were LTS (mfollow-up 39.4mo): 16% D+EP; 14% D+T+EP; 9% EP - Higher proportn of pts treated with D+T+EP and PDL1 >1% were LTS at 18mo + 36mo (not TMB) - More LTS pts completed EPx4 @OncoAlert @myESMO #LCSM
DrJNaidoo's tweet image. #ELCC Longerm survivors (LTS) from 1L CASPIAN trial in ES SCLC: - 94 pts were LTS (mfollow-up 39.4mo): 16% D+EP; 14% D+T+EP; 9% EP - Higher proportn of pts treated with D+T+EP and PDL1 >1% were LTS at 18mo + 36mo (not TMB) - More LTS pts completed EPx4 @OncoAlert @myESMO #LCSM
0
14
35
5
0
JcbenitezMD's profile picture. Scientist Physician, Lung cancer, MPM & Thymic tumors at HU Virgen de la Victoria. PhD in Translational research program @UniversitatBarcelona. YI LCG @EORTC
Jose Carlos Benitez
 @JcbenitezMD
Mar 26, 2021

Should CNS lesions be screened for Thymic Carcinoma? 5% CNS disease prevalence in RYTHMIC nationwide cohort. #ELCC @BenjaminBesseMD

JcbenitezMD's tweet image. Should CNS lesions be screened for Thymic Carcinoma? 5% CNS disease prevalence in RYTHMIC nationwide cohort. #ELCC @BenjaminBesseMD
0
5
21
2
0
DrJNaidoo's profile picture. Professor of Medical Oncology @CancerCentreIre | Thoracic Oncologist | Immunotherapy & Immune toxicity | Adjunct faculty Johns Hopkins University
Jarushka Naidoo
 @DrJNaidoo
Mar 27, 2021

#ELCC Pitfalls & controversies of IO in nsclc Ongoing talk by @MartinReck2 identifies: - >100 io combo trials - multi-arm trials such as HUDSON likely will be the future & identify which combo’s are of greatest interest @OncoAlert #LCSM

DrJNaidoo's tweet image. #ELCC Pitfalls & controversies of IO in nsclc Ongoing talk by @MartinReck2 identifies: - >100 io combo trials - multi-arm trials such as HUDSON likely will be the future & identify which combo’s are of greatest interest @OncoAlert #LCSM
DrJNaidoo's tweet image. #ELCC Pitfalls & controversies of IO in nsclc Ongoing talk by @MartinReck2 identifies: - >100 io combo trials - multi-arm trials such as HUDSON likely will be the future & identify which combo’s are of greatest interest @OncoAlert #LCSM
0
3
16
0
0
BairdAM's profile picture. Researcher @tcddublin @CancerInstIRE; @myESMO PAWG; @LungCommunity Treasurer; @IASLC STARS mentor; @Donegal_SAL Views are my own #LCSM #Donegal
Dr Anne-Marie Baird
 @BairdAM
Mar 20, 2024

Natasha Leighl kicks off #ELCC by giving a flavour of what lies ahead over the next few days #LCSM #ESMOAmbassadors

BairdAM's tweet image. Natasha Leighl kicks off #ELCC by giving a flavour of what lies ahead over the next few days #LCSM #ESMOAmbassadors
1
0
10
0
378
DrJNaidoo's profile picture. Professor of Medical Oncology @CancerCentreIre | Thoracic Oncologist | Immunotherapy & Immune toxicity | Adjunct faculty Johns Hopkins University
Jarushka Naidoo
 @DrJNaidoo
Mar 31, 2022

#ELCC Furmonertinib v Gefitinib in 1L EGFR-mt NSCLC - mPFS 20.8 v 11.1mo - HR 0.44 p<0.0001 - 11% G3+ TRAEs Another 3rd gen EGFR TKI in 1L. Next steps will be to understand what this may add to the landscape: ?improved access in certain areas ?cost @Oncoalert #LCSM @myesmo

DrJNaidoo's tweet image. #ELCC Furmonertinib v Gefitinib in 1L EGFR-mt NSCLC - mPFS 20.8 v 11.1mo - HR 0.44 p&amp;lt;0.0001 - 11% G3+ TRAEs Another 3rd gen EGFR TKI in 1L. Next steps will be to understand what this may add to the landscape: ?improved access in certain areas ?cost @Oncoalert #LCSM @myesmo
DrJNaidoo's tweet image. #ELCC Furmonertinib v Gefitinib in 1L EGFR-mt NSCLC - mPFS 20.8 v 11.1mo - HR 0.44 p&amp;lt;0.0001 - 11% G3+ TRAEs Another 3rd gen EGFR TKI in 1L. Next steps will be to understand what this may add to the landscape: ?improved access in certain areas ?cost @Oncoalert #LCSM @myesmo
DrJNaidoo's tweet image. #ELCC Furmonertinib v Gefitinib in 1L EGFR-mt NSCLC - mPFS 20.8 v 11.1mo - HR 0.44 p&amp;lt;0.0001 - 11% G3+ TRAEs Another 3rd gen EGFR TKI in 1L. Next steps will be to understand what this may add to the landscape: ?improved access in certain areas ?cost @Oncoalert #LCSM @myesmo
DrJNaidoo's tweet image. #ELCC Furmonertinib v Gefitinib in 1L EGFR-mt NSCLC - mPFS 20.8 v 11.1mo - HR 0.44 p&amp;lt;0.0001 - 11% G3+ TRAEs Another 3rd gen EGFR TKI in 1L. Next steps will be to understand what this may add to the landscape: ?improved access in certain areas ?cost @Oncoalert #LCSM @myesmo
1
11
29
1
0
DrJNaidoo's profile picture. Professor of Medical Oncology @CancerCentreIre | Thoracic Oncologist | Immunotherapy & Immune toxicity | Adjunct faculty Johns Hopkins University
Jarushka Naidoo
 @DrJNaidoo
Mar 27, 2021

#ELCC Role of surgery in IO trials by Sven Hillinger, key points: - trials explore perioperative IO +/- RT +/- chemo in early stage nsclc - some studies in oligometastatic dx (e.g. ETOP-CHESS) - opportunities to untangle challenges such as pseudoprogression @OncoAlert #LCSM

DrJNaidoo's tweet image. #ELCC Role of surgery in IO trials by Sven Hillinger, key points: - trials explore perioperative IO +/- RT +/- chemo in early stage nsclc - some studies in oligometastatic dx (e.g. ETOP-CHESS) - opportunities to untangle challenges such as pseudoprogression @OncoAlert #LCSM
DrJNaidoo's tweet image. #ELCC Role of surgery in IO trials by Sven Hillinger, key points: - trials explore perioperative IO +/- RT +/- chemo in early stage nsclc - some studies in oligometastatic dx (e.g. ETOP-CHESS) - opportunities to untangle challenges such as pseudoprogression @OncoAlert #LCSM
0
3
10
1
0
bmassutis's profile picture. Medical oncologist, clinical researcher. Focus lung cancer. Born in Majorca. World citizen. Major concerns: human inequality and blue planet environment. @gecp
Bartomeu Massuti
 @bmassutis
Mar 30, 2023

Next challenge in Perioperative approach in NSCLC: tailoring treatment according risk but value of addition of postop therapy need to be confirmed in specific designed trials ⁦@APassaroMD⁩ ⁦@MARIANOPROVENCI⁩ ⁦@FordePatrick⁩ @OncoAlert at #ELCC #LCSM

bmassutis's tweet image. Next challenge in Perioperative approach in NSCLC: tailoring treatment according risk but value of addition of postop therapy need to be confirmed in specific designed trials ⁦@APassaroMD⁩ ⁦@MARIANOPROVENCI⁩ ⁦@FordePatrick⁩ @OncoAlert at #ELCC #LCSM
0
7
22
2
4K
allion9093's profile picture. Proud retired Head Teacher of Knightsridge Primary School & Knightsridge Early Years Centre💚💛
Allison Kennedy
 @allion9093
Jan 17, 2019

Looking forward to an evening of celebration as we applaud our amazing EY practitioners across WL @LoveWestLothian @wlelc @donnamcmaster @KnightsridgeEYC @KnightsridgePr1 Congratulations to you all! #Froebel #ELCC

allion9093's tweet image. Looking forward to an evening of celebration as we applaud our amazing EY practitioners across WL @LoveWestLothian @wlelc @donnamcmaster @KnightsridgeEYC @KnightsridgePr1 Congratulations to you all! #Froebel #ELCC
allion9093's tweet image. Looking forward to an evening of celebration as we applaud our amazing EY practitioners across WL @LoveWestLothian @wlelc @donnamcmaster @KnightsridgeEYC @KnightsridgePr1 Congratulations to you all! #Froebel #ELCC
allion9093's tweet image. Looking forward to an evening of celebration as we applaud our amazing EY practitioners across WL @LoveWestLothian @wlelc @donnamcmaster @KnightsridgeEYC @KnightsridgePr1 Congratulations to you all! #Froebel #ELCC
allion9093's tweet image. Looking forward to an evening of celebration as we applaud our amazing EY practitioners across WL @LoveWestLothian @wlelc @donnamcmaster @KnightsridgeEYC @KnightsridgePr1 Congratulations to you all! #Froebel #ELCC
2
1
23
0
0
DrJNaidoo's profile picture. Professor of Medical Oncology @CancerCentreIre | Thoracic Oncologist | Immunotherapy & Immune toxicity | Adjunct faculty Johns Hopkins University
Jarushka Naidoo
 @DrJNaidoo
Mar 30, 2023

#ELCC Day 1 Highlight: Amivantamab long-term outcomes + biology in EGFR exon20ins+ NSCLC: - 48% pts have clinical benefit at 1yr - 47.2% pts alive at 2yrs - Baseline ctDNA alteratns in RAS/RAF/MEK assoc with less time on tx @myESMO @Piuchagarrido #LCSM dailyreporter.esmo.org/european-lung-…

DrJNaidoo's tweet image. #ELCC Day 1 Highlight: Amivantamab long-term outcomes + biology in EGFR exon20ins+ NSCLC: - 48% pts have clinical benefit at 1yr - 47.2% pts alive at 2yrs - Baseline ctDNA alteratns in RAS/RAF/MEK assoc with less time on tx @myESMO @Piuchagarrido #LCSM dailyreporter.esmo.org/european-lung-…
0
25
62
12
9K
DrJNaidoo's profile picture. Professor of Medical Oncology @CancerCentreIre | Thoracic Oncologist | Immunotherapy & Immune toxicity | Adjunct faculty Johns Hopkins University
Jarushka Naidoo
 @DrJNaidoo
Mar 31, 2022

#ELCC The 7habits of highly effective molecular testing by Fernando Lopes Rios: - molec testing must be broad - optimize execution via tight test/report systems - panels change, updates will be needed - create a multi-d team+molec tumor boards #LCSM meets Stephen Covey @myESMO

DrJNaidoo's tweet image. #ELCC The 7habits of highly effective molecular testing by Fernando Lopes Rios: - molec testing must be broad - optimize execution via tight test/report systems - panels change, updates will be needed - create a multi-d team+molec tumor boards #LCSM meets Stephen Covey @myESMO
DrJNaidoo's tweet image. #ELCC The 7habits of highly effective molecular testing by Fernando Lopes Rios: - molec testing must be broad - optimize execution via tight test/report systems - panels change, updates will be needed - create a multi-d team+molec tumor boards #LCSM meets Stephen Covey @myESMO
DrJNaidoo's tweet image. #ELCC The 7habits of highly effective molecular testing by Fernando Lopes Rios: - molec testing must be broad - optimize execution via tight test/report systems - panels change, updates will be needed - create a multi-d team+molec tumor boards #LCSM meets Stephen Covey @myESMO
DrJNaidoo's tweet image. #ELCC The 7habits of highly effective molecular testing by Fernando Lopes Rios: - molec testing must be broad - optimize execution via tight test/report systems - panels change, updates will be needed - create a multi-d team+molec tumor boards #LCSM meets Stephen Covey @myESMO
1
7
33
1
0
bmassutis's profile picture. Medical oncologist, clinical researcher. Focus lung cancer. Born in Majorca. World citizen. Major concerns: human inequality and blue planet environment. @gecp
Bartomeu Massuti
 @bmassutis
Mar 30, 2023

EMPOWER 3 updated results: Cemiplimab added to CT improves outcomes for both histologies but not for PD-L1 negative tumors subgroups at #ELCC 2023 ⁦@OncoAlert⁩

bmassutis's tweet image. EMPOWER 3 updated results: Cemiplimab added to CT improves outcomes for both histologies but not for PD-L1 negative tumors subgroups at #ELCC 2023 ⁦@OncoAlert⁩
bmassutis's tweet image. EMPOWER 3 updated results: Cemiplimab added to CT improves outcomes for both histologies but not for PD-L1 negative tumors subgroups at #ELCC 2023 ⁦@OncoAlert⁩
1
11
22
3
3K
DrJNaidoo's profile picture. Professor of Medical Oncology @CancerCentreIre | Thoracic Oncologist | Immunotherapy & Immune toxicity | Adjunct faculty Johns Hopkins University
Jarushka Naidoo
 @DrJNaidoo
Mar 23, 2024

#ELCC ADCs: the promising new therapy? Discussing all things antibody-drug conjugates, join me, #EgbertSmit #IgnatioWistuba & ⁦@peters_solange⁩ in Forum Hall today at 10am #ESMOambassadors #ELCC24 ⁦@myESMO⁩ ⁦⁦@CancerCentreIre⁩ ⁦@RCSI_Irl⁩⁩

DrJNaidoo's tweet image. #ELCC ADCs: the promising new therapy? Discussing all things antibody-drug conjugates, join me, #EgbertSmit #IgnatioWistuba &amp;amp; ⁦@peters_solange⁩ in Forum Hall today at 10am #ESMOambassadors #ELCC24 ⁦@myESMO⁩ ⁦⁦@CancerCentreIre⁩ ⁦@RCSI_Irl⁩⁩
2
10
38
1
5K
bmassutis's profile picture. Medical oncologist, clinical researcher. Focus lung cancer. Born in Majorca. World citizen. Major concerns: human inequality and blue planet environment. @gecp
Bartomeu Massuti
 @bmassutis
Mar 30, 2023

Relapsed SCLC another frustrating scenario: Topotecan poor results are not yet improved but research continues #ELCC ⁦@OncoAlert⁩

bmassutis's tweet image. Relapsed SCLC another frustrating scenario: Topotecan poor results are not yet improved but research continues #ELCC ⁦@OncoAlert⁩
bmassutis's tweet image. Relapsed SCLC another frustrating scenario: Topotecan poor results are not yet improved but research continues #ELCC ⁦@OncoAlert⁩
0
6
10
3
2K

Something went wrong.


Something went wrong.


United States Trends